Tesamorelin

Tesamorelin is an FDA-approved prescription medicine, sold as EGRIFTA, with one indication: reducing excess abdominal fat in HIV-infected adults with lipodystrophy. The FDA approved it on 10 November 2010. The approval rests on two randomised, placebo-controlled Phase 3 trials of 412 and 404 patients, and the result was not subtle. Visceral fat, measured by CT scan, fell 18 percent and 14 percent over 26 weeks, while on placebo it moved by about 2 percent.

The market sells it as something broader. Marketing tends to drop the HIV half of the indication and present tesamorelin as a general abdominal-fat treatment. The label closes off the obvious next leap on its own: tesamorelin is not indicated for weight loss, because it has a weight-neutral effect. It changes where fat sits. It does not change what the scale says.

Two more facts belong up front. The fat reduction lasts only while treatment does, and patients moved to placebo regained visceral fat within six months. And the drug pushes IGF-1 hard: after 26 weeks, 36 percent of treated patients had IGF-1 more than 3 standard deviation scores above normal, and the label says the long-term effects of that are unknown.

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, or GHRH, the hypothalamic signal that tells the pituitary to make growth hormone. Structurally it is the full 44-amino-acid sequence of human GHRH with a hexenoyl group, a six-carbon chain, attached at the front end. Older papers call it TH9507.

Native GHRH was never practical as a drug because the enzyme DPP4 breaks it down rapidly in the body. Adding a hydrophobic chain was the fix, and tesamorelin is the result. It contains no growth hormone. It prompts the patient's own pituitary to release more, and the hope behind GHRH-based treatment was that this would keep growth hormone release closer to its natural pulsing pattern and leave IGF-1 feedback intact.

The current US product is EGRIFTA WR. A second formulation, EGRIFTA SV, carries its own label, and the label states plainly that the two are not substitutable.

One Step Upstream of Growth Hormone

GHRH acts on the somatotroph cells of the pituitary to drive the synthesis and pulsatile release of growth hormone. In laboratory testing, tesamorelin binds and stimulates the human GHRH receptor with similar potency to the body's own hormone. Growth hormone then acts on fat cells, liver, muscle, bone and cartilage, and much of its effect runs through IGF-1 made in the liver and peripheral tissue.

The response is large and specific. In the two pivotal trials IGF-1 rose by about 107 to 108 ng/mL over 26 weeks on tesamorelin, against little or no change on placebo. Other pituitary hormones, including TSH, LH, ACTH and prolactin, showed no clinically significant change. The drug clears fast, with a mean half-life of 11 minutes in healthy subjects, so what persists is the downstream hormonal signal rather than the molecule.

Why Fat Moves and Weight Does Not

Growth hormone is both lipolytic and anabolic: it releases stored fat and builds lean tissue. The trials show both at once. Over 26 weeks trunk fat fell by 1.0 kg and 0.8 kg in the two studies, while lean body mass rose by 1.3 kg and 1.2 kg. The two roughly cancel, which is why the label calls the drug weight neutral. The fat that goes is mostly visceral, the deep abdominal fat around the organs. A 2026 meta-analysis found no significant reduction in subcutaneous fat or BMI.

The HIV connection is not incidental. Low growth hormone levels were found in HIV patients with central fat accumulation, and that observation is what led to tesamorelin's development for this condition.

The approval is real, and that is what makes tesamorelin easy to stretch. Each overreach starts from a true sentence and drops a clause.

Dropping the HIV clause. The indication is excess abdominal fat in HIV-infected adults with lipodystrophy. The two pivotal trials, the JAMA liver-fat trial and all five trials in the 2026 meta-analysis enrolled people with HIV, and the pivotal trials excluded anyone with diabetes. Selling tesamorelin as a general abdominal-fat treatment takes a result from one studied group and hands it to a group that was not studied.

Treating IGF-1 as the goal. Raising IGF-1 is how the drug works, and the label treats it as a risk to watch rather than a target to chase. The effects of prolonged elevation are unknown, and persistent levels above 3 standard deviation scores are listed as a reason to consider stopping, particularly when the fat response is weak. A higher lab number is mechanism, not benefit.

Promoting it for fatty liver. Liver fat did fall, modestly, in 48 treated people with HIV who were not selected for liver disease. That is a promising lead and nothing more. As a 2012 review put it, limited data support off-label uses.

Borrowing the approval for anti-aging. Growth hormone is culturally tied to youth and recovery, and an FDA approval sounds like a seal on all of it. The approval covers one fat depot in one population. None of the trials measured aging, recovery or performance.

The label is specific about what can go wrong, and the list is longer than the casual conversation suggests.

Who cannot take it. The label contraindicates it in people with a disrupted hypothalamic-pituitary axis (after pituitary surgery, pituitary tumour, head irradiation or head trauma, for example), in active malignancy, in known hypersensitivity to the drug and in pregnancy. Because growth hormone is a known growth factor, any earlier cancer must be inactive with treatment complete before starting, and evidence of recurrence ends treatment.

Glucose. In the trials 5 percent of treated patients reached an HbA1c of 6.5 percent or higher, against 1 percent on placebo, a hazard ratio of 3.3. The 2026 meta-analysis reported no glucose perturbation across five trials, but the label still lists glucose intolerance and diabetes as a warning, and a 2011 review noted that the extra diabetes could offset any cardiovascular gain.

IGF-1. After 26 weeks, 47 percent of treated patients were above 2 standard deviation scores and 36 percent above 3.

Day to day. Injection site reactions occurred in 25 percent of treated patients against 14 percent on placebo during the first 26 weeks. Fluid retention shows up as joint pain, swelling and carpal tunnel syndrome, usually transient. Hypersensitivity reactions occurred in 4 percent. Half of patients had antibodies to tesamorelin by 26 weeks, though visceral fat and IGF-1 responses were similar with or without them. On the liver, LiverTox reports no link to aminotransferase elevations or clinically apparent liver injury.

For an adult with HIV and the abdominal fat pattern the trials enrolled, tesamorelin is a proven, approved option. It reliably cuts visceral fat, trims the waist a little, adds some lean mass and probably lowers liver fat. That decision belongs with the clinician managing the HIV, and the label's list of warnings is part of it.

What the evidence supports: a meaningful reduction in visceral fat in that population, maintained only while treatment continues, at the cost of a higher chance of rising blood sugar and sustained IGF-1 elevation.

What the evidence does not support: weight loss, use in people without HIV, cardiovascular protection, or any anti-aging or performance claim built on raising growth hormone. A 2012 review flagged the lack of long-term safety data, and the 2025 label still says long-term cardiovascular safety has not been established.

If you do not have HIV, the honest summary is that the approval tells you how well tesamorelin works for someone else. The costs on the label would come along either way.

Not a weight-loss drug. The label says it directly: tesamorelin is not indicated for weight loss management because it has a weight-neutral effect. In both pivotal trials average body weight moved by less than a kilogram, on tesamorelin and on placebo alike.

Not a permanent change. When treated patients were switched to placebo, visceral fat rose 22 percent and 16 percent over the next 26 weeks. The reduction holds only while the drug is being taken.

Not growth hormone. It contains none. It asks the pituitary to release more, and the label contraindicates it wherever the hypothalamic-pituitary axis has been disrupted.

Not permitted in tested sport. WADA prohibits tesamorelin under S2.2.4 and names it among the GHRH analogues. FDA approval does not take a substance off the Prohibited List.

Tesamorelin is a drug that works, and most of the attention it gets is for something it was never shown to do. Both halves of that sentence matter to me.

The first half deserves to be said without hedging. Two Phase 3 trials, more than 800 people, a CT-measured primary endpoint and a placebo arm: visceral fat fell, and it fell reliably. The FDA approved it on that basis in 2010, and the label was last revised in 2025. I am not going to describe a result like that in the cautious tone I use for compounds whose evidence is a handful of rats.

The second half deserves the same plainness. The label itself says it is not a weight-loss drug. The trials enrolled people with HIV. The benefit fades when the drug stops, and the price of it is a higher chance of diabetes and an IGF-1 level whose long-term effects nobody can yet vouch for. Those are the label's numbers, not my caution.

Where I land: if you have HIV and this fat pattern, this is a real option to raise with the clinician who manages your care. If you do not, the approval is evidence about other people, and I will not dress it up as evidence about you.